1. Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006. 368:1171–1179.
2. Ueno A, Kawamura T, Ogawa A, Takayasu H. Relation of spontaneous passage of ureteral calculi to size. Urology. 1977. 10:544–546.
3. Carstensen HE, Hansen TS. Stones in the ureter. Acta Chir Scand Suppl. 1973. 433:66–71.
4. Malin JM Jr, Deane RF, Boyarsky S. Characterisation of adrenergic receptors in human ureter. Br J Urol. 1970. 42:171–174.
5. Yamaguchi K, Minei S, Yamazaki T, Kaya H, Okada K. Characterization of ureteral lesions associated with impacted stones. Int J Urol. 1999. 6:281–285.
6. Porpiglia F, Vaccino D, Billia M, Renard J, Cracco C, Ghignone G, et al. Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association? Eur Urol. 2006. 50:339–344.
7. Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006. 97:747–751.
8. Sun X, He L, Ge W, Lv J. Efficacy of selective alpha1D-blocker naftopidil as medical expulsive therapy for distal ureteral stones. J Urol. 2009. 181:1716–1720.
9. Wolf JS Jr. Treatment selection and outcomes: ureteral calculi. Urol Clin North Am. 2007. 34:421–430.
10. Wang CJ, Huang SW, Chang CH. Efficacy of an alpha1 blocker in expulsive therapy of lower ureteral stones. J Endourol. 2008. 22:41–46.
11. Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al. The American Urological Association. Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. J Urol. 1997. 158:1915–1921.
12. Tchey DU, Ha YS, Kim WT, Yun SJ, Lee SC, Kim WJ. Expectant management of ureter stones: outcome and clinical factors of spontaneous passage in a single institution's experience. Korean J Urol. 2011. 52:847–851.
13. Bensalah K, Pearle M, Lotan Y. Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones. Eur Urol. 2008. 53:411–418.
14. Gettman MT, Segura JW. Management of ureteric stones: issues and controversies. BJU Int. 2005. 95:Suppl 2. 85–93.
15. Hubner WA, Irby P, Stoller ML. Natural history and current concepts for the treatment of small ureteral calculi. Eur Urol. 1993. 24:172–176.
16. Coll DM, Varanelli MJ, Smith RC. Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol. 2002. 178:101–103.
17. Shokeir AA. Renal colic: pathophysiology, diagnosis and treatment. Eur Urol. 2001. 39:241–249.
18. Borghi L, Meschi T, Amato F, Novarini A, Giannini A, Quarantelli C, et al. Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double-blind, placebo-controlled study. J Urol. 1994. 152:1095–1098.
19. Porpiglia F, Destefanis P, Fiori C, Fontana D. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology. 2000. 56:579–582.
20. Sigala S, Dellabella M, Milanese G, Fornari S, Faccoli S, Palazzolo F, et al. Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn. 2005. 24:142–148.
21. Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K. Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol. 2007. 14:749–753.
22. Itano N, Ferlic E, Nunez-Nateras R, Humphreys MR. Medical expulsive therapy in a tertiary care emergency department. Urology. 2012. 79:1242–1246.
23. Tsuzaka Y, Matsushima H, Kaneko T, Yamaguchi T, Homma Y. Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: a randomized controlled study in Japanese male patients. Int J Urol. 2011. 18:792–795.
24. Zhou SG, Lu JL, Hui JH. Comparing efficacy of α1D-receptor antagonist naftopidil and α1A/D-receptor antagonist tamsulosin in management of distal ureteral stones. World J Urol. 2011. 29:767–771.
25. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999. 79:447–454.
26. Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol. 2009. 56:455–471.
27. Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol. 2004. 172:568–571.
28. Yildiz O, Doganay M, Aygen B, Guven M, Kelestimur F, Tutuu A. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care. 2002. 6:251–259.
29. Nayak S, Acharjya B. Deflazacort versus other glucocorticoids: a comparison. Indian J Dermatol. 2008. 53:167–170.
30. Kinnman E, Nygards EB, Hansson P. Peripheral alpha-adrenoreceptors are involved in the development of capsaicin induced ongoing and stimulus evoked pain in humans. Pain. 1997. 69:79–85.